- Clinical Trials
- April 2024
- 60 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Report
- April 2024
- 180 Pages
Global
From €4706EUR$4,900USD£4,052GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- May 2022
- 208 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Clinical Trials
- October 2020
- 196 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Clinical Trials
- December 2019
- 239 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Clinical Trials
- December 2019
- 565 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Drug Pipelines
- October 2020
- 166 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- September 2023
- 113 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- August 2022
- 125 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- June 2021
- 96 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- August 2020
- 90 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- May 2022
- 113 Pages
Global
From €1921EUR$2,000USD£1,654GBP
The Ischemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on drugs used to treat ischemia, a condition caused by reduced blood flow to the heart. Ischemia drugs are used to reduce the risk of heart attack, stroke, and other cardiovascular events. These drugs can be used to treat both acute and chronic ischemia, and can be administered orally, intravenously, or through injections. Common ischemia drugs include antiplatelet agents, anticoagulants, and statins.
Ischemia drugs are widely used in the treatment of cardiovascular diseases, and are an important part of the cardiovascular drugs market. Companies in the Ischemia Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Show Less Read more
